Ankylosing Spondylitis Disease Activity Score (ASDAS) by anti-drug

Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity

Cureus, Tumor Necrosis Factor-Alpha (+489 G/A) Polymorphism Can Predict the Response to Adalimumab in Chinese Han Patients With Ankylosing Spondylitis

WO2021067465A1 - Treating spondyloarthritic and psoriatic conditions with upadacitinib - Google Patents

PDF) The Value of the Ankylosing Spondylitis Disease Activity Score (Asdas) in Evaluating Disease Activity in Patients with Axial Spondyloarthritis

Ankylosing Spondylitis Disease Activity Score (ASDAS) by anti-drug

MBBS, MMed (Int Med), FAMS (Rheum), FACR, RhMSUS, RMSK - ppt download

Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis

Interrupted course of antitumor necrosis factor alpha therapy versus combined nonsteroidal anti-inflammatory drug therapy and physiotherapy in patients with ankylosing spondylitis: A comparative study Abdelrahman SK, M. Mostafa TF - J Med

Frontiers The BASDAI Cut-Off for Disease Activity Corresponding to the ASDAS Scores in a Taiwanese Cohort of Ankylosing Spondylitis

The predictability of ASDAS on drug survival in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry - Jinhyun Kim, Min Jung Kim, Geun Young Oh, Sun Kyung Lee

Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it

Clinical Tools to Assess and Monitor Spondyloarthritis

Video Abstract: Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) Versus ASDAS

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3